The patient Fatigue Severity Score (FSS) also significantly decreased (Figure 3) after maraviroc and pravastatin which correlated with decrease in sCD40L (r = 0.5, p = 0.001), VEGF (r = 0.5, p = 0.001), TNF-alpha (r = 0.7, p = 4e-5), IL-2 (r = 0.6, p = 0.0005), and GM-CSF (r = 0.5, p = 0.004), again suggesting that targeting the monocytic-platelet-endothelial axis can alleviate PASC associated fatigue. This evidence concerns the gene CSF2 and long COVID-19.